Sio Gene Therapies (SIOX) Financials

$0.48

$0.01 (1.70%)

As on 07-Feb-2024 15:59EDT

Market cap

$35 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15	Mar-14	Mar-13
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	0.80	--	--	--
Gross Profit	--	--	-0.80	--	--	--
Operating Expenses	29.37	71.56	42.20	69.17	127.02	213.32
Operating Profit (EBIT)	-29.58	-72.27	-34.30	-67.81	-127.02	-213.32
Other Income	--	--	--	--	--	--
Profit before Tax	-28.55	-71.63	-32.64	-72.19	-128.93	-220.65
Provision for Tax	-0.38	0.26	-0.21	0.44	0.13	0.92
Profit after Tax (Net Income)	-28.17	-71.89	-32.43	-72.63	-129.07	-221.57
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-28.83	-71.89	-32.43	-72.63	-129.07	-221.57

Liabilities ($ Mln)	TTM	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15	Mar-14	Mar-13
Shareholder's Funds	45.12	60.35	123.37	61.56	56.21	71.29
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.20	1.73	0.93	0.08	22.99	42.93
Current Liabilities	2.15	13.00	10.85	32.04	43.50	46.58
Total Liabilities	49.42	75.08	135.15	93.68	122.71	160.79

Assets ($ Mln)	TTM	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15	Mar-14	Mar-13
Non-Current Assets	--	3.34	2.81	8.25	8.12	2.52
Current Assets	47.27	71.74	132.33	85.43	114.58	158.26
Total Assets	49.42	75.08	135.15	93.68	122.71	160.79
Total Debt*	--	2.52	1.24	16.39	44.18	52.68
Net Current Assets	45.12	58.73	121.49	53.39	71.09	111.69

Cashflow ($ Mln)	TTM	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15	Mar-14	Mar-13
Cash From Operating Activities	--	-60.35	-46.59	-67.47	-134.21	-190.35
Cash Flow from Investing Activities	--	3.65	12.39	-0.26	-0.20	-4.28
Cash from Financing Activities	--	1.44	73.62	41.48	87.07	136.40
Net Cash Inflow / Outflow	--	--	39.42	--	--	--

Financials Ratios	TTM	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15	Mar-14	Mar-13
Adjusted EPS ($)	--	-0.38	-0.98	-0.62	-2.91	-8.07
Cash EPS ($)	--	--	-0.98	-0.58	-2.78	-7.91
Adjusted Book Value ($)	--	--	0.83	2.37	2.46	3.51
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	-0.83	-0.90	-2.70	-8.39
Free Cash Flow per Share ($)	--	--	-0.84	-0.90	-2.71	-8.40

Profitability Ratios	TTM	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15	Mar-14	Mar-13
ROCE (%)	--	--	-76.69	-32.02	-81.45	-115.06
ROE (%)	--	-58.13	-78.26	-35.07	-123.34	-202.46
ROA (%)	--	-35.68	-68.39	-28.34	-67.13	-91.05
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15	Mar-14	Mar-13
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	--	52.37	-110.67	49.41	45.25	41.88
Net Profit Growth (%)	--	54.49	-121.70	55.35	43.73	41.75
EPS Growth (%)	--	55.78	-0.58	0.79	0.64	0.53
Book Value Growth (%)	--	-41.64	--	--	--	--

Valuation Ratios	TTM	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15	Mar-14	Mar-13
Price / Earnings	--	--	-0.68	-4.19	-0.84	-0.16
Price / Book Value	--	0.78	0.81	1.10	0.99	0.38
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	--	0.37	0.17	-0.43	0.14	0.34
Close Price ($)	--	0.44	0.67	2.61	2.44	10.64
High Price ($)	--	1.53	2.95	5.74	10.80	52.72
Low Price ($)	--	0.23	0.55	1.86	1.41	7.44
Market Cap ($ Cr)	--	35.36	--	--	--	--

Solvency Ratios	TTM	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15	Mar-14	Mar-13
Debt to Equity	--	--	0.04	0.01	0.27	0.79
Short term debt to equity ratio	--	--	0.01	0.00	0.26	0.38
Current Ratio	--	21.97	5.52	12.20	2.67	2.63
Quick Ratio	--	21.97	--	12.75	2.72	--
Interest Coverage	--	-34.86	-2,676.56	-42.93	-15.49	-16.45

Operating Efficiency Ratios	TTM	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15	Mar-14	Mar-13
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	-1,761.34	--	--
Payable days	--	--	--	1,314.95	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.